Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Carlos Paya, Atul Humar, Ed Dominguez, Kenneth Washburn, Emily Blumberg, Barbara Alexander, Richard Freeman, Nigel Heaton, Mark D. Pescovitz

Research output: Contribution to journalArticle

637 Citations (Scopus)

Abstract

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant (SOT) recipients of organs from seropositive donors (D+/R-). In this randomised, prospective, double-blind, double-dummy study, 364 CMV D+/R- patients received valganciclovir 900 mg once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft loss and safety were analyzed up to 6 and 12 months post-transplant. End-point committee-defined CMV disease developed in 12.1% and 15.2% of valganciclovir and ganciclovir patients, respectively, by 6 months, though with a difference in the relative efficacy of valganciclovir and ganciclovir between organs (i.e. an organ type-treatment interaction). By 12 months, respective incidences were 17.2% and 18.4%, and the incidence of investigator-treated CMV disease events was comparable in the valganciclovir (30.5%) and ganciclovir (28.0%) arms. CMV viremia during prophylaxis was significantly lower with valganciclovir (2.9% vs. 10.4%; p = 0.001), but was comparable by 12 months (48.5% valganciclovir vs 48.8% ganciclovir). Time-to-onset of CMV disease and to viremia were delayed with valganciclovir; rates of acute allograft rejection were generally lower with valganciclovir. Except for a higher incidence of neutropenia with valganciclovir (8.2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalAmerican Journal of Transplantation
Volume4
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Ganciclovir
Cytomegalovirus
Transplants
Safety
Viremia
Incidence
Transplant Recipients
valganciclovir
Graft Rejection
Neutropenia
Double-Blind Method
Allografts
Arm
Research Personnel
Tissue Donors

Keywords

  • Cytomegalovirus
  • Ganciclovir
  • Neutropenia
  • Valganciclovir

ASJC Scopus subject areas

  • Immunology

Cite this

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients. / Paya, Carlos; Humar, Atul; Dominguez, Ed; Washburn, Kenneth; Blumberg, Emily; Alexander, Barbara; Freeman, Richard; Heaton, Nigel; Pescovitz, Mark D.

In: American Journal of Transplantation, Vol. 4, No. 4, 04.2004, p. 611-620.

Research output: Contribution to journalArticle

Paya, C, Humar, A, Dominguez, E, Washburn, K, Blumberg, E, Alexander, B, Freeman, R, Heaton, N & Pescovitz, MD 2004, 'Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients', American Journal of Transplantation, vol. 4, no. 4, pp. 611-620. https://doi.org/10.1111/j.1600-6143.2004.00382.x
Paya, Carlos ; Humar, Atul ; Dominguez, Ed ; Washburn, Kenneth ; Blumberg, Emily ; Alexander, Barbara ; Freeman, Richard ; Heaton, Nigel ; Pescovitz, Mark D. / Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 4. pp. 611-620.
@article{580571cddf574cdfb3c4417991277b04,
title = "Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients",
abstract = "We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant (SOT) recipients of organs from seropositive donors (D+/R-). In this randomised, prospective, double-blind, double-dummy study, 364 CMV D+/R- patients received valganciclovir 900 mg once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft loss and safety were analyzed up to 6 and 12 months post-transplant. End-point committee-defined CMV disease developed in 12.1{\%} and 15.2{\%} of valganciclovir and ganciclovir patients, respectively, by 6 months, though with a difference in the relative efficacy of valganciclovir and ganciclovir between organs (i.e. an organ type-treatment interaction). By 12 months, respective incidences were 17.2{\%} and 18.4{\%}, and the incidence of investigator-treated CMV disease events was comparable in the valganciclovir (30.5{\%}) and ganciclovir (28.0{\%}) arms. CMV viremia during prophylaxis was significantly lower with valganciclovir (2.9{\%} vs. 10.4{\%}; p = 0.001), but was comparable by 12 months (48.5{\%} valganciclovir vs 48.8{\%} ganciclovir). Time-to-onset of CMV disease and to viremia were delayed with valganciclovir; rates of acute allograft rejection were generally lower with valganciclovir. Except for a higher incidence of neutropenia with valganciclovir (8.2{\%}, vs 3.2{\%} ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients.",
keywords = "Cytomegalovirus, Ganciclovir, Neutropenia, Valganciclovir",
author = "Carlos Paya and Atul Humar and Ed Dominguez and Kenneth Washburn and Emily Blumberg and Barbara Alexander and Richard Freeman and Nigel Heaton and Pescovitz, {Mark D.}",
year = "2004",
month = "4",
doi = "10.1111/j.1600-6143.2004.00382.x",
language = "English (US)",
volume = "4",
pages = "611--620",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

AU - Paya, Carlos

AU - Humar, Atul

AU - Dominguez, Ed

AU - Washburn, Kenneth

AU - Blumberg, Emily

AU - Alexander, Barbara

AU - Freeman, Richard

AU - Heaton, Nigel

AU - Pescovitz, Mark D.

PY - 2004/4

Y1 - 2004/4

N2 - We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant (SOT) recipients of organs from seropositive donors (D+/R-). In this randomised, prospective, double-blind, double-dummy study, 364 CMV D+/R- patients received valganciclovir 900 mg once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft loss and safety were analyzed up to 6 and 12 months post-transplant. End-point committee-defined CMV disease developed in 12.1% and 15.2% of valganciclovir and ganciclovir patients, respectively, by 6 months, though with a difference in the relative efficacy of valganciclovir and ganciclovir between organs (i.e. an organ type-treatment interaction). By 12 months, respective incidences were 17.2% and 18.4%, and the incidence of investigator-treated CMV disease events was comparable in the valganciclovir (30.5%) and ganciclovir (28.0%) arms. CMV viremia during prophylaxis was significantly lower with valganciclovir (2.9% vs. 10.4%; p = 0.001), but was comparable by 12 months (48.5% valganciclovir vs 48.8% ganciclovir). Time-to-onset of CMV disease and to viremia were delayed with valganciclovir; rates of acute allograft rejection were generally lower with valganciclovir. Except for a higher incidence of neutropenia with valganciclovir (8.2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients.

AB - We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant (SOT) recipients of organs from seropositive donors (D+/R-). In this randomised, prospective, double-blind, double-dummy study, 364 CMV D+/R- patients received valganciclovir 900 mg once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft loss and safety were analyzed up to 6 and 12 months post-transplant. End-point committee-defined CMV disease developed in 12.1% and 15.2% of valganciclovir and ganciclovir patients, respectively, by 6 months, though with a difference in the relative efficacy of valganciclovir and ganciclovir between organs (i.e. an organ type-treatment interaction). By 12 months, respective incidences were 17.2% and 18.4%, and the incidence of investigator-treated CMV disease events was comparable in the valganciclovir (30.5%) and ganciclovir (28.0%) arms. CMV viremia during prophylaxis was significantly lower with valganciclovir (2.9% vs. 10.4%; p = 0.001), but was comparable by 12 months (48.5% valganciclovir vs 48.8% ganciclovir). Time-to-onset of CMV disease and to viremia were delayed with valganciclovir; rates of acute allograft rejection were generally lower with valganciclovir. Except for a higher incidence of neutropenia with valganciclovir (8.2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients.

KW - Cytomegalovirus

KW - Ganciclovir

KW - Neutropenia

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=1942469969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942469969&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00382.x

DO - 10.1111/j.1600-6143.2004.00382.x

M3 - Article

C2 - 15023154

AN - SCOPUS:1942469969

VL - 4

SP - 611

EP - 620

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -